Andrew J Levine, Chirag Thadani, Virawudh Soontornniyomkij, Manuel F Lopez-Aranda, Yoelvis Garcia Mesa, Scott Kitchen, Valerie Rezek, Alcino Silva, Dennis L Kolson
UNLABELLED: Neurocognitive deficits are prevalent among people living with HIV, likely due to chronic inflammation and oxidative stress in the brain. To date, no pharmaceutical treatments beyond antiretroviral therapy (ARV) has been shown to reduce risk for, or severity of, HIV-associated neurocognitive disorder. Here we investigate a novel compound, CDDO-Me, with documented neuroprotective effects via activation of the nrf2 and inhibition of the NFkB pathways. METHODS: We conducted three studies to assess the efficacy of CDDO-Me alone or in combination with antiretroviral therapy in humanized mice infected with HIV; behavioral, histopathological, and immunohistochemical...
December 13, 2023: Research Square